Travere Therapeutics Inc
TVTX24.850USD
+0.660+2.73%
收盘 09/19, 16:00（美东）报价延迟15分钟
2.21B总市值
亏损市盈率 TTM
关于 Travere Therapeutics Inc 公司
Travere Therapeutics, Inc. 是一家生物制药公司。该公司专注于为患有罕见肾脏和代谢疾病的患者识别、开发和提供改变生活的疗法。其产品 FILSPARI (sparsentan) 适用于降低患有原发性 IgAN 且有快速疾病进展风险的成人患者的蛋白尿。Sparsentan 还处于局灶节段性肾小球硬化症 (FSGS) 的后期开发阶段。该公司的 Pegtibatinase 是一种新型的试验性人类酶替代候选药物，正在评估用于治疗经典同型胱氨酸尿症 (HCU)，这是一种罕见的代谢性疾病。其商业产品 Thiola 和 Thiola EC 用于治疗胱氨酸尿症，这是一种罕见的遗传性胱氨酸转运障碍，会导致尿液中胱氨酸水平高和复发性肾结石的形成。该公司还致力于识别 Alagille 综合征 (ALGS) 的潜在小分子疗法。
公司简介
公司代码TVTX
公司名称Travere Therapeutics Inc
上市日期Jul 23, 2003
CEODr. Eric M. Dube, Ph.D.
员工数量385
证券类型Ordinary Share
年结日Jul 23
公司地址3611 Valley Centre Dr
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92130
电话18889697879
网址https://travere.com/
公司代码TVTX
上市日期Jul 23, 2003
CEODr. Eric M. Dube, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
129.71K
--
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+8.72%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
75.38K
+4.36%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+14.61%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Independent Director
49.00K
+15.29%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
47.41K
+3.77%
Ms. Elizabeth E. Reed
Ms. Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
39.89K
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
31.00K
+26.53%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Director
Independent Director
28.88K
+29.05%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Independent Director
Independent Director
28.88K
+29.05%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
129.71K
--
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+8.72%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
75.38K
+4.36%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+14.61%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Independent Director
49.00K
+15.29%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
47.41K
+3.77%
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
FILSPARI
55.88M
0.00%
Tiopronin Products
19.98M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
FILSPARI
55.88M
0.00%
Tiopronin Products
19.98M
0.00%
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
12.72%
Armistice Capital LLC
9.96%
BlackRock Institutional Trust Company, N.A.
7.51%
The Vanguard Group, Inc.
6.70%
Macquarie Investment Management
5.72%
其他
57.39%
持股股东
持股股东
占比
Janus Henderson Investors
12.72%
Armistice Capital LLC
9.96%
BlackRock Institutional Trust Company, N.A.
7.51%
The Vanguard Group, Inc.
6.70%
Macquarie Investment Management
5.72%
其他
57.39%
股东类型
持股股东
占比
Investment Advisor
40.51%
Investment Advisor/Hedge Fund
35.14%
Hedge Fund
33.68%
Research Firm
4.65%
Private Equity
2.06%
Venture Capital
1.29%
Individual Investor
0.83%
Bank and Trust
0.35%
Pension Fund
0.29%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
470
104.47M
117.23%
-11.51M
2025Q1
484
101.83M
114.67%
-16.19M
2024Q4
461
96.91M
109.26%
-9.67M
2024Q3
448
85.09M
109.18%
-32.25M
2024Q2
444
90.35M
118.12%
-28.07M
2024Q1
437
90.02M
118.29%
-22.39M
2023Q4
428
87.89M
116.97%
-15.26M
2023Q3
417
84.96M
113.19%
-18.05M
2023Q2
411
85.35M
113.93%
-14.35M
2023Q1
418
86.52M
116.25%
+3.17M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
7.53M
8.48%
+3.47M
+85.50%
Mar 31, 2025
Armistice Capital LLC
8.87M
9.99%
+1.51M
+20.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.72M
7.56%
+84.30K
+1.27%
Mar 31, 2025
The Vanguard Group, Inc.
5.00M
5.63%
-1.73M
-25.73%
Mar 31, 2025
Macquarie Investment Management
4.80M
5.4%
+537.76K
+12.62%
Mar 31, 2025
State Street Global Advisors (US)
3.65M
4.11%
-120.52K
-3.20%
Mar 31, 2025
Emerald Advisers LLC
3.20M
3.6%
-28.46K
-0.88%
Mar 31, 2025
Adage Capital Management, L.P.
2.18M
2.46%
+1.81M
+479.86%
Mar 31, 2025
Renaissance Technologies LLC
2.70M
3.04%
+293.30K
+12.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.98M
2.23%
+134.36K
+7.29%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
F/m Emerald Life Sciences Innovation ETF
5.4%
Invesco Pharmaceuticals ETF
3.05%
SPDR S&P Biotech ETF
0.55%
Franklin Genomic Advancements ETF
0.36%
First Trust Small Cap Growth AlphaDEX Fund
0.31%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Invesco Nasdaq Biotechnology ETF
0.17%
First Trust Small Cap Core Alphadex Fund
0.15%
iShares Biotechnology ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
查看更多
F/m Emerald Life Sciences Innovation ETF
占比5.4%
Invesco Pharmaceuticals ETF
占比3.05%
SPDR S&P Biotech ETF
占比0.55%
Franklin Genomic Advancements ETF
占比0.36%
First Trust Small Cap Growth AlphaDEX Fund
占比0.31%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.31%
Invesco Nasdaq Biotechnology ETF
占比0.17%
First Trust Small Cap Core Alphadex Fund
占比0.15%
iShares Biotechnology ETF
占比0.15%
ProShares Ultra Nasdaq Biotechnology
占比0.15%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
